NAOV Stock Overview
Through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NanoVibronix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$1.52 |
| 52 Week Low | US$0.46 |
| Beta | 1.62 |
| 1 Month Change | -8.21% |
| 3 Month Change | -15.26% |
| 1 Year Change | -44.31% |
| 3 Year Change | -97.29% |
| 5 Year Change | -98.99% |
| Change since IPO | -99.16% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable
Dec 09
NanoVibronix receives extension to satisfy Nasdaq bid price requirement
Oct 19NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract
Sep 23Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?
Jul 08Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?
Mar 22Is NanoVibronix (NASDAQ:NAOV) In A Good Position To Deliver On Growth Plans?
Dec 01NanoVibronix: Portable Ultrasonic Therapeutic Devices
Sep 01NanoVibronix (NASDAQ:NAOV) Is In A Good Position To Deliver On Growth Plans
Aug 17NanoVibronix announces expansion of distribution pact for its ultrasound devices
Dec 11NanoVibronix secures $6M in equity capital
Dec 02NanoVibronix reports Q3 results
Nov 17Shareholder Returns
| NAOV | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.1% | -3.4% | -3.5% |
| 1Y | -44.3% | 9.0% | 22.1% |
Return vs Industry: NAOV underperformed the US Medical Equipment industry which returned 9% over the past year.
Return vs Market: NAOV underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| NAOV volatility | |
|---|---|
| NAOV Average Weekly Movement | 12.5% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NAOV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NAOV's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 13 | Brian Murphy | www.nanovibronix.com |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company’s product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.
NanoVibronix, Inc. Fundamentals Summary
| NAOV fundamental statistics | |
|---|---|
| Market cap | US$2.31m |
| Earnings (TTM) | -US$3.09m |
| Revenue (TTM) | US$3.29m |
0.7x
P/S Ratio-0.7x
P/E RatioIs NAOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAOV income statement (TTM) | |
|---|---|
| Revenue | US$3.29m |
| Cost of Revenue | US$1.33m |
| Gross Profit | US$1.96m |
| Other Expenses | US$5.05m |
| Earnings | -US$3.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.82 |
| Gross Margin | 59.62% |
| Net Profit Margin | -93.80% |
| Debt/Equity Ratio | 0% |
How did NAOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 02:52 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NanoVibronix, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Dawson James Securities |
| Joseph Gomes | Wm Smith & Co. |
| Brian Marckx | Zacks Investment Research Inc. |